Chesley Taft & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.4M | Sell |
20,347
-77
| -0.4% | -$78.7K | 0.95% | 26 |
|
|
2026
Q1 | $18.8M | Sell |
20,424
-2,017
| -9% | -$2.04M | 0.79% | 41 |
|
|
2025
Q4 | $24.1M | Buy |
22,441
+1,518
| +7% | +$1.45M | 0.95% | 29 |
|
|
2025
Q3 | $16M | Sell |
20,923
-1,879
| -8% | -$1.4M | 0.68% | 42 |
|
|
2025
Q2 | $17.8M | Sell |
22,802
-233
| -1% | -$181K | 0.79% | 35 |
|
|
2025
Q1 | $19M | Buy |
23,035
+712
| +3% | +$592K | 0.92% | 33 |
|
|
2024
Q4 | $17.2M | Sell |
22,323
-60
| -0.3% | -$49.7K | 0.8% | 36 |
|
|
2024
Q3 | $19.8M | Sell |
22,383
-170
| -0.8% | -$153K | 0.95% | 34 |
|
|
2024
Q2 | $20.4M | Buy |
22,553
+1,163
| +5% | +$930K | 1.02% | 32 |
|
|
2024
Q1 | $16.6M | Sell |
21,390
-125
| -0.6% | -$89K | 0.85% | 37 |
|
|
2023
Q4 | $12.5M | Buy |
21,515
+3,864
| +22% | +$2.26M | 0.7% | 44 |
|
|
2023
Q3 | $9.48M | Sell |
17,651
-922
| -5% | -$475K | 0.62% | 45 |
|
|
2023
Q2 | $8.71M | Sell |
18,573
-1,524
| -8% | -$639K | 0.53% | 55 |
|
|
2023
Q1 | $6.9M | Sell |
20,097
-401
| -2% | -$135K | 0.45% | 62 |
|
|
2022
Q4 | $7.5M | Sell |
20,498
-2,577
| -11% | -$914K | 0.52% | 54 |
|
|
2022
Q3 | $7.46M | Buy |
23,075
+130
| +0.6% | +$41.2K | 0.55% | 50 |
|
|
2022
Q2 | $7.44M | Buy |
22,945
+200
| +0.9% | +$60K | 0.51% | 54 |
|
|
2022
Q1 | $7.01M | Buy |
22,745
+10
| +0% | +$2.57K | 0.41% | 64 |
|
|
2021
Q4 | $6.28M | Buy |
22,735
+65
| +0.3% | +$16.5K | 0.33% | 73 |
|
|
2021
Q3 | $5.24M | Buy |
22,670
+415
| +2% | +$102K | 0.3% | 79 |
|
|
2021
Q2 | $5.11M | Buy |
22,255
+110
| +0.5% | +$22.1K | 0.29% | 80 |
|
|
2021
Q1 | $4.09M | Buy |
22,145
+250
| +1% | +$48.9K | 0.24% | 89 |
|
|
2020
Q4 | $3.7M | Sell |
21,895
-430
| -2% | -$64.2K | 0.24% | 89 |
|
|
2020
Q3 | $3.31M | Sell |
22,325
-900
| -4% | -$139K | 0.23% | 88 |
|
|
2020
Q2 | $3.81M | Buy |
23,225
+585
| +3% | +$89.8K | 0.29% | 79 |
|
|
2020
Q1 | $3.14M | Buy |
22,640
+1,475
| +7% | +$203K | 0.29% | 79 |
|
|
2019
Q4 | $2.78M | Buy |
21,165
+240
| +1% | +$27.8K | 0.2% | 97 |
|
|
2019
Q3 | $2.34M | Sell |
20,925
-560
| -3% | -$62.3K | 0.18% | 103 |
|
|
2019
Q2 | $2.38M | Buy |
21,485
+125
| +0.6% | +$14.7K | 0.19% | 99 |
|
|
2019
Q1 | $2.77M | Buy |
21,360
+1,570
| +8% | +$191K | 0.23% | 88 |
|
|
2018
Q4 | $2.29M | Buy |
19,790
+15,870
| +405% | +$1.77M | 0.22% | 92 |
|
|
2018
Q3 | $421K | Sell |
3,920
-350
| -8% | -$35K | 0.03% | 231 |
|
|
2018
Q2 | $364K | Sell |
4,270
-380
| -8% | -$31.2K | 0.03% | 229 |
|
|
2018
Q1 | $360K | Sell |
4,650
-379
| -8% | -$30.5K | 0.03% | 229 |
|
|
2017
Q4 | $425K | Sell |
5,029
-14
| -0.3% | -$1.19K | 0.04% | 232 |
|
|
2017
Q3 | $431K | Sell |
5,043
-114
| -2% | -$9.35K | 0.04% | 227 |
|
|
2017
Q2 | $424K | Buy |
5,157
+2
| +0% | +$163 | 0.04% | 230 |
|
|
2017
Q1 | $434K | Buy |
5,155
+2
| +0% | +$160 | 0.04% | 228 |
|
|
2016
Q4 | $379K | Buy |
5,153
+368
| +8% | +$27.4K | 0.04% | 231 |
|
|
2016
Q3 | $384K | Buy |
4,785
+2
| +0% | +$160 | 0.04% | 215 |
|
|
2016
Q2 | $377K | Buy |
4,783
+3
| +0.1% | +$226 | 0.04% | 219 |
|
|
2016
Q1 | $344K | Buy |
4,780
+356
| +8% | +$26.9K | 0.04% | 215 |
|
|
2015
Q4 | $373K | Sell |
4,424
-398
| -8% | -$33K | 0.04% | 215 |
|
|
2015
Q3 | $404K | Buy |
4,822
+2
| +0% | +$169 | 0.04% | 188 |
|
|
2015
Q2 | $402K | Sell |
4,820
-13
| -0.3% | -$991 | 0.04% | 189 |
|
|
2015
Q1 | $351K | Sell |
4,833
-1,064
| -18% | -$75.8K | 0.04% | 200 |
|
|
2014
Q4 | $407K | Buy |
5,897
+2
| +0% | +$135 | 0.04% | 193 |
|
|
2014
Q3 | $382K | Sell |
5,895
-1,281
| -18% | -$81.1K | 0.04% | 198 |
|
|
2014
Q2 | $446K | Buy |
7,176
+3
| +0% | +$179 | 0.05% | 190 |
|
|
2014
Q1 | $422K | Buy |
7,173
+303
| +4% | +$16.9K | 0.05% | 193 |
|
|
2013
Q4 | $350K | Hold |
6,870
| – | – | 0.03% | 229 |
|
|
2013
Q3 | $346K | Buy |
6,870
+300
| +5% | +$15.7K | 0.04% | 225 |
|
|
2013
Q2 | $323K | Buy |
+6,570
| New | +$357K | 0.04% | 225 |
|
Other funds holding LLY
Chesley Taft & Associates's LLY Position: Q2 2026 in Review
Chesley Taft & Associates reduced its Eli Lilly (LLY) stake by 0.38% in Q2 2026, selling an estimated $78.7K and leaving 20,347 shares worth $24.4M. The position accounts for 0.95% of the portfolio, ranked #26.
Chesley Taft & Associates first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Chesley Taft & Associates held 20,347 shares of Eli Lilly worth $24.4M as of Q2 2026.
- Chesley Taft & Associates sold 77 Eli Lilly shares in Q2 2026, an estimated $78.7K.
- Eli Lilly made up 0.95% of Chesley Taft & Associates's portfolio in Q2 2026, its #26 holding.
- Chesley Taft & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.